Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei’s presence in the chronic disease therapy market.
Chenan Bio’s Profile
Chenan Bio, incubated by Zhirui Investment in 2015, is a high-tech company specializing in the research, development, and production of therapeutic drugs for chronic diseases, including diabetes and obesity. The company has a robust pipeline of over ten investigational programs.
Product Pipeline
Chenan Bio’s product pipeline includes a liraglutide biosimilar prepared for market filing, generic versions of semaglutide (for diabetes) and insulin degludec with completed Phase III trials, and copycats of semaglutide (for weight loss) and insulin degludec, insulin aspart at Phase III stages. This diverse portfolio positions Chenan Bio as a significant player in the chronic disease treatment sector.
Strategic Implications
The acquisition by Zhifei Biological underscores its commitment to expanding its offerings in chronic disease therapies. By leveraging Chenan Bio’s robust R&D capabilities and product pipeline, Zhifei aims to enhance its market competitiveness and provide broader treatment options for patients with chronic conditions.-Fineline Info & Tech
Leave a Reply